Skip to main content
NCBI home page
International Journal of Molecular Medicine logoLink to International Journal of Molecular Medicine
. 2018 Nov 26;43(2):868–878. doi: 10.3892/ijmm.2018.3998

Expression of FKBP52 in the ovaries of PCOS rats

Shiyan Song 1, Yong Tan 2,✉
PMCID: PMC6317667  PMID: 30483787

Abstract

The present study aimed to examine the expression of FK-506 binding protein 52 (FKBP52) in the ovary tissues of rats with polycystic ovarian syndrome (PCOS) and its action on mediating androgen receptor (AR) through the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway. PCOS model rats were established by dehydroepiandrosterone injection. Enzyme-linked immunosorbent assay (ELISA) measured serum sex hormones. Hematoxylin and eosin (H&E) staining was used to examine histological changes of the ovarian tissues. The expression levels of FKBP52 were detected by immunohistochemical (IHC) staining, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis and western blotting (WB). In addition, RT-qPCR analysis was used to detect the mRNA expression of AR, and WB was used to detect the protein expression levels of AR, ERK1/2 and phosphorylated (p-) ERK1/2. In granulosa cell (GC) experiments, primary GCs were extracted and cultured. FKBP4 is the FKBP52-encoding gene, therefore, adenovirus vectors Ad-Oe-FKBP4-EGFP and Ad-siRNA-FKBP4-EGFP were constructed to examine the association among the above factors using the RT-qPCR and WB methods. In the animal experiment, the vaginal smear, H&E staining and ELISA results showed that the PCOS model was successfully established. The IHC staining revealed that the expression of FKBP52 in the GCs of the PCOS model group was higher than the remaining groups (P<0.01). The mRNA and expression levels of FKBP52 and AR in the PCOS model rats were significantly increased, when compared with levels in the other rats (P<0.05). The expression level of p-ERK1/2 was also higher (P<0.05). In the GC experiment, following overexpression of the FKBP4 gene, the mRNA and expression levels of FKBP52 and AR were increased (P<0.05). The expression level of p-ERK1/2 was also increased (P<0.05). Following FKBP4 gene silencing, the mRNA and expression levels of FKBP52 and AR were decreased (P<0.05). The expression level of ERK1/2 was also decreased (P<0.05). However, the expression level of p-ERK1/2 was increased (P<0.05). In conclusion, the upregulation of co-chaperone FKBP52 may mediate the activation of AR through the MAPK/ERK pathway.

Key words: polycystic ovarian syndrome, FK-506 binding protein 52, androgen receptor, mitogen-activated protein kinase/extracellular signal-regulated kinase pathway, adenovirus vectors

Introduction

Polycystic ovarian syndrome (PCOS), which has been renamed metabolic reproductive syndrome, is the most common but little-known reproductive endocrine dysfunction and metabolic disorder in women worldwide (1,2). It is characterized by hyperandrogenism, ovarian polycystic changes and rarity in ovulation or anovulation, and is often accompanied with obesity and insulin resistance (3-5). Diabetes, cardiovascular disease and cancer are its long-term complications. The prevalence of PCOS in Chinese women aged between 12 and 44 years was reported to be 7.4%, according to the recommended diagnostic criteria for PCOS by the Androgen Excess Society (2006), and there is currently a gradual upward trend (6).

FK-506 binding protein 52 (FKBP52) is a subfamily of the FK506 binding protein family, and is commonly used as immunosuppressant. In 1985, FKBP52 was first identified by Tai et al in the establishment of an antibody against the EC1 epitope of rabbit uterine progesterone receptor complex (7). It was named due to its relative molecular weight of ~52 kDa, and to date, it has been investigated in various experimental studies (8). As one of the Hsp90 co-chaperones that modify steroid hormone receptor activity, including regulation of receptor maturation, hormone binding and nuclear translocation, FKBP52 is a positive regulator of androgen receptor (AR) (9). It has been reported to be overexpressed in prostate cancer cell lines, and FK506 has an inhibitory influence on androgen-stimulated cell growth (10). Prostate needle biopsies of human patients were also found to have elevated FKBP52 levels (11). Furthermore, a number of compounds that suppress the adjustment by FKBP52 on AR function interdicted androgen-dependent gene expression and cell proliferation in prostate cancer cells (12). Preceding studies have also reported that male 52KO mice manifested phenotypes in accordance with partial androgen insensitivity (9,13).

There have been few reports on FKBP52 in PCOS. In a previous study, by comparing normal women of childbearing age with patients with PCOS using gene chip technology, it was revealed that FKBP52 protein-coding genes were different, and this may be closely associated with abnormal androgen PCOS and obesity phenotype (14). In conclusion, FKBP52 may be considered a therapeutic target in diseases that rely on AR signaling pathways, and may be a contributor to endocrine-related and metabolic diseases, including PCOS.

The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is a classic MAPK signal transduction pathway. It is involved in cell growth, differentiation, environmental stress adaptation, the inflammatory response and other important cell physiology/pathology processes. Activated AR in the cytoplasm may interact with several signaling molecules, which in turn converge on the activation of MAPK/ERK (15,16). Studies on 5α-dihydrotestost eroneresponsiveness in prostate cancer cells showed increased phosphorylation of ERK-1/2 within 5 min, in a dose-dependent manner, and this response was AR-dependent as no effect was observed in AR-negative PC-3 prostate cancer cells (17). PCOS with insulin resistance and PCOS without insulin resistance showed statistically significant increases than control group (P<0.05) in expression of ERK1/2 in human luteinized granulosa cells (GCs); there was no significant difference between the PCOS groups (18).

The present study aimed to investigate the expression of FKBP52 in the ovarian tissues of PCOS rats. It is well-known that FKBP4 is the FKBP52-encoding gene. The adenovirus vectors Ad-Oe-FKBP4-EGFP and Ad-siRNA-FKBP4-EGFP were constructed to assess how FKBP52 mediates AR through the MAPK/ERK pathway following GC transfection.

Materials and methods

Animal experiments Experimental animals

A total of 60 female Sprague-Dawley (SD) rats were provided by Shanghai Jie Esprit Experimental Animal Co., Ltd. [Shanghai, China; certificate no. SCXK (Shanghai) 2013-0006]. The animals were of specific-pathogen-free (SPF) grade and were 21 days old, with a mean body weight of 58±4 g.

Replication of a PCOS animal model

The 60 21-day-old female SD rats of SPF grade were randomly divided into three groups following common feeding for 2 days; In the PCOS model (PM) group (n=20), the rats were administered with dehydroepiandrosterone (DHEA; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 6 mg/(100 g. d) + 0.2 ml of injectable soybean oil via hypodermic injection for 35 consecutive days (19,20); in the oil control (OC) group (n=20), the rats were administered with 0.2 ml of injectable soybean oil via hypodermic injection over the same period; in the normal control (NC) group (n=20), the rats underwent no specific treatment. All animals were housed with a normal diet every day under a 12 h light/dark cycle at a temperature of 20-25°C.

The model was successfully established when rats of the PM group showed loss of their estrous cycle. All rats were detected for body weight, ovarian weight, organ coefficient and vaginal smear, and serum was collected and analyzed via an enzyme-linked immunosorbent assay (ELISA). In addition, four ovaries of each group were randomly selected for histological examination of ovarian tissues to further evaluate the efficiency of the established model.

Specimen collection

Following the final day of modeling, all rats were weighed and then anesthetized with 2% sodium pentobarbital (30 mg/kg) for laparotomy to collect abdominal aorta blood and ovarian tissue specimens. When the 60 ovarian tissue specimens were weighed, the four ovarian specimens of each group were rapidly fixed in 4% paraformaldehyde fixative, embedded with paraffin, and cut into sections for hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC). The rest were stored in a refrigerator at −80°C, for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis and western blotting (WB). Serum was collected following centrifugation of all blood samples at 1000 × g for 10 min.

H&E and IHC staining

Following 4 h of fixation in 4% paraformaldehyde fixative, the rat ovarian tissue specimens were subjected to conventional dehydration followed by paraffin-embedding and thin sectioning (4-µm thick). H&E staining was performed to examine the pathological structures of the rat ovary. IHC staining was conducted to detect the expression of FKBP52 in rat ovaries with an optical microscope (Leica DM2500, Leica Microsystems GmbH, Wetzlar, Germany).

ELISA

All serum samples were manipulated according to the manufacturer’s protocol of every ELISA kit (Elabscience, Wuhan, China) for follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P) and total testosterone (T). Experiments were performed in triplicate and repeated three times.

Fluorescence RT-qPCR analysis

A total of eight ovarian tissue specimens from each group were milled separately with TRIzol reagent (Beyotime Institute of Biotechnology, Haimen, China) using an IKA T 10 basic ULTRA-TURRAX disperser. A NanoDrop 2000 spectrophotometer was used to measure RNA concentration following extraction of total RNA from every specimen. Subsequently, the RNA was reverse-transcribed into cDNA using a reverse transcription kit (Takara Bio, Inc., Otsu, Japan). Eventually, 1.0 µl cDNA was used as a template for PCR amplification ChamQ™ SYBR® qPCR Master mix (High ROX Premixed) was purchased from Vazyme (Nanjing, China). The 10 µl qPCR reaction mixture included the following: cDNA 1 µl, forward primer (10 µM) 0.5 µl, reverse primer (10 µM) 0.5 µl, SYBR qPCR mix 5 µl, ddH2O 3 µl. The primer sequences (Sangon Biotech Co., Ltd., Shanghai, China) used were as follows: GAPDH forward, 5′-GACATGCCGCCTGGAGAAAC-3′ and reverse, 5′-AGCCCAGGATGCCCTTTAGT-3′, FKBP52 upstream, 5′-CACTACACTGGCTGGCTGCT-3′ and downstream, 5′-TGGTTGCCACAGCAATATCC-3′; AR upstream, 5′-CCTTCACAGCAGCAGTCAGC-3′ and downstream, 5′-CCTGATCTGGAGGAGCTGGT-3′. The amplification conditions were as follows: Pre-denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 sec and annealing at 60°C for 1 min. Data were collected and used for relative quantitative analysis with the 2−∆∆Cq method (21). The relative mRNA expression level was obtained by comparing data of the experimental group with those of the control group. The experiments were performed in triplicate and repeated three times.

WB

A total of eight ovarian tissue specimens from each group were milled separately with RIPA lysis buffer using IKA T 10 basic ULTRA-TURRAX. The detection of protein concentration was performed according to the manufacturer’s protocol of the Enhanced BCA Protein Assay kit (Beyotime Institute of Biotechnology) following total protein extraction from every specimen. The electrophoretic separation of known antigenic proteins were run using the sodium dodecyl sulfate polyacrylamide gel electrophoresis method; 50 µg protein were separated by 10% SDS-PAGE and then transferred onto a polyvinylidene fluoride membrane. Subsequently, the membranes were blocked in 5% bovine serum albumin (2 h at room temperature) and then incubated with primary (4°C overnight) and secondary antibodies (2 h at room temperature). Anti-FKBP52 antibody (EPR6618; cat. no. ab129097; 1:1,000), anti-androgen receptor antibody (EP670Y; cat. no. ab52615; 1:1,000) and anti-ERK1 + ERK2 antibody (EPR17526; cat. no. ab184699; 1:10,000) were purchased from Abcam (Cambridge, UK). Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® rabbit monoclonal antibody (cat. no. 4370; 1:2,000), GAPDH (14C10) rabbit monoclonal antibody (cat. no. 2118; 1:1,000) and anti-rabbit IgG and HRP-linked antibody (cat. no. 7074; 1:50,000) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). The blots were developed with Immobilon Western Chemiluminescent HRP Substrate (Merck KGaA). GAPDH served as an internal control. Quantitative analysis of protein expression was conducted by using ImageJ software 1.8.0 (National Institutes of Health, Bethesda, MD, USA).

Cell experiments

Isolation and culture of GCs

A total of 10 female SD rats were provided by Shanghai Jie Esprit Experimental Animal Co., Ltd. [certificate no. SCXK (Shanghai) 2013-0006]. The animals were of SPF grade and were 21 days old, with a mean body weight of 58±4 g. All animals were housed with a normal diet every day. Every rat was administrated with pregnant mare serum gonadotropin (20 IU; Sansheng Pharmaceutical Industry Co., Ltd., Ningbo, China) through intraperitoneal injection following 2 days of common feeding. After 48 h, the animals were anesthetized with 2% sodium pentobarbital (30 mg/kg), sacrificed by cervical dislocation, and soaked in 75% alcohol for 30 min. All ovaries, which were obtained by laparotomy, were placed into PBS and transferred into DMEM-F12 medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) following washing once again with PBS.

The GCs were harvested by puncturing the follicles with microsurgical forceps, and ~95% of the GCs were negatively stained using a Trypan blue assay. The GCs were then centrifuged at 300 × g, 4°C for 5 min, filtered with a cell sieve, and centrifuged again. The pellet was resuspended at 5×105/ml with DMEM-F12 medium for the RT-qPCR and WB methods, and at 5×104/ml for H&E, immunocytochemistry (ICC), and immunofluorescence (IF) techniques in 6-well plates. The GCs were cultured in the incubator (37°C, 5% CO2) and, after 72 h, the cell adherence rate was ~80%.

Morphology and identification of GCs

H&E staining was performed to observe the morphology of the GCs with an Olympus inverted microscope (Olympus Corporation, Tokyo, Japan). As FSH receptor (FSHR) is only expressed in GCs, ICC and IF were conducted to identify its purity. It met the requirements of subsequent trials when the positive rate was >95%.

Adenovirus vector transfection of GCs

The adenovirus vectors Ad-Oe-FKBP4-EGFP (2×1010 PFU/ml), Oe negative control virus (1011 PFU/ml), Ad-siRNA-FKBP4-EGFP (2×1010 PFU/ml) and RNAi negative control virus (5×1010 PFU/ml), provided by Shanghai GeneChem Co., Ltd. (Shanghai, China) were constructed to transfect GCs. First, the multiplicity of infection (MOI) was ascertained by using different diluted concentrations of adenovirus vectors (MOI = virus titer x virus volume/cell numbers). The adenovirus vectors were diluted according to a concentration gradient between 10−2 and 10−7. When cell adherence rate reached ~80% in 96-well plates, the medium was discarded. The GCs were then cultured with medium containing different concentrations of virus vectors. After 12 h, the normal medium was replaced. The expression of green fluorescence in the GCs was observed following 48 h of infection (Cell transfection rate = number of green fluorescent cells/total number of cells ×100%). When the rate reached ~80%, the virus concentration was considered the optimal dilution concentration.

Ad-Oe-FKBP4-EGFP transfection of GCs

The GCs were divided into three groups: Normal control group (CO group), EGFP-Oe group (EO group), and FKBP4-EGFP-Oe group (FO group). When the cell attachment rate reached ~80%, the medium was discarded. Based on previous pre-experiment results, DMEM-F12 medium was added to the CO group, DMEM-F12 medium with Oe negative control virus (2 µl) was added to the EO group, and DMEM-F12 medium with FKBP4-Oe virus (20 µl) was added to the FO group. After 12 h, the medium was replaced with normal DMEM-F12 medium, and RNA and protein were obtained following 48 h of infection.

Ad-siRNA-FKBP4-EGFP transfection of GCs

The GCs were divided into three groups: Normal control group (CR group), EGFP-RNAi group (ER group), and FKBP4-EGFP-RNAi group (FR group). When the cell attachment rate reached ~80%, the medium was discarded. Based on previous pre-experiment results, DMEM-F12 medium was added to the CR group, DMEM-F12 medium with RNAi negative control virus (2 µl) was added to the ER group, and DMEM-F12 medium with FKBP4-RNAi virus (20 µl) was added to the FR group. After 12 h, the medium was then replaced with normal DMEM-F12 medium, and RNA and protein were obtained following 48 h of infection.

Statistical analysis

The statistical analysis was performed using GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla, CA, USA). The measurement data are expressed as the mean ± standard deviation. A normality test and homogeneity of variance test were performed prior to making comparison between the groups. Comparisons of three samples were performed using one-way analysis of variance at the 0.05 level and multiple comparison between the groups was performed using Tukey method. Variables that did not meet a normal distribution were analyzed using a Kruskal-Wallis test.

Results

PCOS rats show loss of regular estrous cycle

At 35 days following DHEA treatment, the rats in the PM group had lost their regular estrous cycles and all of remained in the estrus period. Microscopy of stained smears of vaginal secretions showed the presence of large numbers of keratinized cells, suggesting anovulation. By contrast, the rats in the NC and OC group had a regular estrous cycle (Fig. 1A).

Figure 1.

Figure 1

Open in a new tab

PCOS model evaluation. (A) Microscopy of stained smears of vaginal secretions (toluidine blue staining; magnification, ×100; n=20 per group). Estrus (keratinized epithelial cells); metaestrus (keratinized epithelial cells, epithelial cells, and white blood cells); anestrus (white blood cells); proestrus (epithelial cells). NC and OC groups had regular estrous cycle, however, rats in the PM group remained in the estrus period and lost their regular estrous cycles, suggesting anovulation. (B) Comparison of body weight, ovarian weight and organ coefficient among the three groups (mean ± SD, n=20 per group). Body weights at 21 and 58 days did not differ significantly among groups, whereas PM group ovarian weight and organ coefficient were significantly lower. (C) Comparison of rat ovarian structure (hematoxylin and eosin staining, ×25 magnification, n=4 per group). Morphological changes of rat ovarian tissue specimens were examined by light microscopy. In the NC and OC groups, microscopic examination revealed the presence of follicles of different developmental stages and a few corpora lutea; granulosa cells were orderly arranged with an intact form, mostly in 6-8 layers. In the PM group, the number of follicles with saccular dilatation increased, whereas follicles of different developmental stages and corpora lutea were rare; granulosa cells were arranged loosely in ~2-3 layers, with atresia of some follicles. This result was consistent with PCOS characteristics. (D) Comparison of FSH, LH, LH/FSH, P, E2, T and E2/T among groups (mean ± SD, n=20 per group). Sex hormones were measured by enzyme-linked immunosorbent assay. No significant differences in FSH, LH or LH/FSH were found. However, E2 and T in the PM group were significantly higher, and E2/T was significantly lower. Experiments were performed in triplicate and repeated three times. ***P<0.0001 and ****P<0.0001 NC group vs. PM group; ##P<0.01 and ####P<0.0001 OC group vs. PM group. PCOS, polycystic ovarian syndrome; PM, PCOS model; NC, normal control; OC, oil control; FSH, follicle stimulating hormone; LH, luteinizing hormone; E2, estradiol; P, progesterone; T, total testosterone; F, follicle; CL, corpora lutea; SD, standard deviation.

Ovarian weight and organ coefficient are decreased in PCOS rats

The body weights of the rats at 21 and 58 days among the three groups showed no statistically significant difference. However, the ovarian weight and organ coefficient of the PM group were significantly lower than those in the other two groups (Fig. 1B).

Pathological structures of rat ovaries

Morphological changes in the rat ovarian tissue specimens were examined by light microscopy. In the NC and OC groups, microscopic examination revealed the presence of follicles of different developmental stages and a few corpora lutea; arrangement of the GCs was orderly with an intact form, mostly in 6-8 layers. In the PM group, the number of follicles with saccular dilatation increased whereas few follicles of different developmental stages and corpora lutea were observed; the GCs were arranged loosely in ~2-3 layers, and with atresia of certain follicles. This result was consistent with PCOS characteristics (Fig. 1C).

PCOS rats have higher E2 and T levels and lower E2/T levels

There were no statistically significant differences in the levels of FSH, LH or LH/FSH in the rats among the three groups. However, the levels of E2 and T in the PM group were significantly higher than those in the other two groups, and E2/T was significantly lower. The experiments were performed in triplicate and repeated three times (Fig. 1D).

FKBP52 is increased in ovarian sections of PCOS rats

FKBP52-positive staining (yellow) was present not only in the nucleus, but also in the cytoplasm among all types of cell in the rat ovary. In the GCs, the expression of FKBP52 in the PM group was higher than in the other two groups (Fig. 2).

Figure 2.

Figure 2

Open in a new tab

Comparison of the expression of FKBP52 in the ovaries of three groups (immunohistochemistry; magnification, ×200; GCs, n=4 per group). FKBP52-positive staining (yellow) was present in the nucleus and cytoplasm (indicated by black triangle) among all types of cells in the rat ovary. In GCs, expression of FKBP52 in the PM group was higher than in the other two groups. **P<0.01 NC group vs. PM group; ##P<0.01 OC group vs. PM group. FKBP52, FK-506 binding protein 52; PM, polycystic ovarian syndrome model; NC, normal control; OC, oil control.

PCOS rats have higher mRNA expression levels of FKBP52 and AR

The mRNA expression levels of FKBP52 and AR in the rat ovarian tissues of the PM group were significantly higher than those in the NC and OC groups. There was no statistically significant difference between the NC and OC groups. The experiments were performed in triplicate and repeated three times (Fig. 3A).

Figure 3.

Figure 3

Open in a new tab

Expression of FKBP52, AR, ERK1/2 and p-ERK1/2 in rats. (A) Comparison of mRNA expression levels of FKBP52 and AR among the three groups (mean ± SD, n=8 per group). The mRNA expression levels of FKBP52 and AR in the rat ovarian tissues of the PM group were significantly higher than those in the NC and OC groups. No significant difference was found between the NC and OC groups (P>0.05). (B) Comparison of protein expression levels of FKBP52, AR, ERK1/2 and p-ERK1/2 among the three groups (mean ± SD, n=8 per group). The protein expression levels of FKBP52, AR and p-ERK1/2 in the rat ovarian tissues of the PM group were significantly higher than those in the NC and OC groups. No significant difference was found between the NC and OC groups. Protein expression of ERK1/2 did not differ significantly among the groups. Experiments were performed in triplicate and repeated three times. *P<0.05, **P<0.01 and ***P<0.001 NC group vs. PM group; #P<0.05, ##P<0.01 and ###P<0.001 OC group vs. PM group. FKBP52, FK-506 binding protein 52; AR, androgen receptor; ERK1/2, extracellular signal-regulated kinase; p-ERK1/2, phosphorylated ERK1/2; PM, polycystic ovarian syndrome model; NC, normal control; OC, oil control; SD, standard deviation.

PCOS rats have higher protein expression levels of FKBP52, AR and p-ERK1/2

The protein expression levels of FKBP52, AR and P-ERK1/2 in the rat ovarian tissues of the PM group were significantly higher than those of the NC and OC groups. There was no statistically significant difference between the NC and OC groups. The protein expression of ERK1/2 did not differ significantly among the three groups. The experiments were performed in triplicate and repeated three times (Fig. 3B).

Morphology and identification of GCs

The GCs exhibited a polygonal or cuboidal appearance under inverted phase contrast microscopy on adhering to the culture surface, proliferating, and spreading to form a monolayer (Fig. 4A). FSHR-positive staining (yellow) was present in the nucleus and the cytoplasm of the GCs (Fig. 4B). Therefore, IF staining was performed. The positive rate was >95%, therefore, the GCs extracted met the requirements of subsequent trials (Fig. 4C).

Figure 4.

Figure 4

Open in a new tab

Morphology and identification of GCs (hematoxylin and eosin staining, magnification, ×200; immunocytochemistry staining, magnification ×200; IF staining, magnification ×400). (A) GCs exhibited polygonal or cuboidal appearance under inverted phase contrast microscopy on adhering to the culture surface, proliferating, and spreading to form a monolayer. (B) FSHR-positive staining (yellow) was present in the nucleus and cytoplasm of GCs. IF staining was performed; (C) the positive rate was >95%, therefore, the GCs extracted met the requirements of subsequent trials. GCs, granulosa cells; FSHR, follicle stimulating hormone receptor; IF, immunofluorescence.

Expression of green fluorescence in GCs

Based on the preliminary trial, appropriate results were obtained following calculation according to the formula of MOI: For the Oe negative control virus, the optimal dilution concentration was 10−3, MOI=200; the optimal dilution concentration of the FKBP4-Oe virus was 10−2, MOI=400; the optimal dilution concentration of RNAi negative control virus was 10−3, MOI=100; the optimal dilution concentration of FKBP4-RNAi virus was 10−2, MOI=400. The cell transfection rate was >80% (Fig. 5A-D).

Figure 5.

Figure 5

Open in a new tab

Expression of green fluorescence in GCs. (A) Oe negative control virus group, 1011 PFU/ml, MOI=200; (B) FKBP4-Oe virus group, 2×1010 PFU/ml, MOI=400; (C) RNAi negative control virus group, 5×1010 PFU/ml, MOI=100; (D) FKBP4-RNAi virus group, 2×1010 PFU/ml, MOI=400). The cell transfection rate was >80%. Magnification, ×100. GCs, granulosa cells; MOI, multiplicity of infection.

mRNA expression levels of FKBP52 and AR increase following overexpression of FKBP4

The mRNA expression levels of FKBP52 and AR in the FO group were significantly higher than those in the CO group and EO group. There was no statistically significant difference between the CO group and EO group. The experiments were performed in triplicate and repeated three times (Fig. 6A).

Figure 6.

Figure 6

Figure 6

Open in a new tab

Expression of FKBP52, AR, ERK1/2 and p-ERK1/2 in GCs. (A) Comparison of the mRNA expression levels of FKBP52 and AR mRNA (mean ± SD, n=9 per group). mRNA expression levels of FKBP52 and AR in the FO group were significantly higher than those in the CO and EO groups. No significant difference was found between the CO and EO groups (P>0.05). (B) Comparison of the protein expression levels of FKBP52, AR, ERK1/2 and p-ERK1/2 (mean ± SD, n=6 per group). Protein expression levels of FKBP52, AR and p-ERK1/2 in the FO group were significantly higher than those in the CO and EO groups. No significant difference was found between the CO and EO groups. Protein expression of ERK1/2 did not differ significantly among the groups. (C) Comparison of the mRNA expression levels of FKBP52 and AR (mean ± SD, n=9 per group). mRNA expression levels of FKBP52 and AR in the FR group were significantly lower than those in the CR and ER groups. No significant difference was found between the CR and ER groups (P>0.05). (D) Comparison of the protein expression levels of FKBP52, AR, ERK1/2 and p-ERK1/2 (mean ± SD, n=6 per group). Protein expression levels of FKBP52, AR and ERK1/2 in the FR group were significantly lower than those in the CR and ER groups. p-ERK1/2 showed the opposite result. No significant difference was found between the CR and ER groups. The experiment was repeated three times. *P<0.05, **P<0.01 and ***P<0.001 NC group vs. PM group; #P<0.05, ##P<0.01 and ###P<0.001 OC group vs. PM group. FKBP52, FK-506 binding protein 52; AR, androgen receptor; ERK1/2, extracellular signal-regulated kinase; p-ERK1/2, phosphorylated ERK1/2; PM, polycystic ovarian syndrome model; NC, normal control; OC, oil control; SD, standard deviation.

Protein expression levels of FKBP52, AR and p-ERK following the overexpression of FKBP4

The protein expression levels of FKBP52, AR and p-ERK1/2 in the FO group were significantly higher than those in the CO group and EO group. There was no statistically significant difference between the CO group and EO group. The protein expression of ERK1/2 did not differ significantly among the three groups. The experiment was repeated three times (Fig. 6B).

mRNA expression levels of FKBP52 and AR decrease following FKBP4 silencing

The mRNA expression levels of FKBP52 and AR in the FR group were significantly lower than those in the CR group and ER group. There was no statistically significant difference between the CR group and ER group. The experiments were performed in triplicate and repeated three times (Fig. 6C).

Protein expression levels of FKBP52, AR and ERK decrease, and that of p-ERK increases following FKBP4 silencing

The protein expression levels of FKBP52, AR and ERK1/2 in the FR group were significantly lower than those in the CR group and ER group, whereas p-ERK showed the opposite result. There was no statistically significant difference between the CR group and ER group. The experiment was repeated three times (Fig. 6D).

Discussion

PCOS is an endocrine disease featuring hyperandrogenism which has a multifactorial pathogenesis and heterogeneous clinical manifestations. Among all clinical manifestations, variant degrees of hyperandrogenism are present in the majority of patients with PCOS. The hyperandrogenism state of ovarian tissues in the PCOS population can lead to dysgenesis.

In the present study, PCOS rats had higher expression levels of FKBP52, AR and p-ERK1/2 in the ovary. Following adenovirus vector transfection of GCs, the protein expression levels of AR, ERK1/2 and p-ERK1/2 changed with FKBP4 gene silencing and overexpression.

PCOS model evaluation

At 35 days post-DHEA treatment, the vaginal smear (Fig. 1A), H&E staining (Fig. 1C), and ELISA results (Fig. 1D) revealed that the PCOS model was successfully established. Differences between rats and humans in the mechanism of ovulation may explain why the ovarian weights and ovarian coefficients of the PM group rats were statistically lower in than the control groups (Fig. 1B).

FKBP52 in reproductive development

Previous studies on two independently derived FKBP52-deficient (52KO) mouse lines served a vital role in the reproductive development of mammals. Male 52KO mice exhibit phenotypes in accordance with partial androgen insensitivity, incorporating dysgenic prostate and seminal vesicles, ambiguous external genitalia covering hypospadias and retention of nipples into adulthood (9,13). They had reduced epididymal sperm counts and motility (22), and the sperm showed abnormal morphology. Therefore, gene knock-out experiments in male mice have revealed FKBP52 as a crucial promoter of physiological AR activity (9,13).

Female 52KO mice were yield as they exhibited normal morphology, ovulation and fertilization. The dysgenesis was the consequence of embryonic implantation and decidualization failure on account of progesterone insensitivity and uterine defects (23-25). In addition, FKBP52 may result in endometriotic lesions, with decreased expression levels of FKBP52 in patients with endometriosis, and increased cell proliferation, inflammation and angiogenesis resulting from progesterone resistance in 52KO mice (26). According to the above-mentioned findings, FKBP52 is important in reproductive development.

FKBP52, AR, and PCOS

Previous studies have provided evidence to support a direct pathological role for AR-mediated signaling in the development of PCOS (27,28). It is an important extraovarian mediator (29). Certain findings have indicated how hyperandrogenism modulates AR ubiquitination, resulting in antral follicle growth arrest in a chronically androgenized PCOS rat model (30).

Few investigations have been performed on the impact of FKBP52 on PCOS. In a comparison of normal women of childbearing age with patients with PCOS using gene chip technology, FKBP52 protein-coding genes were different, and it may be closely associated with abnormal androgen PCOS and obesity phenotype (14). High-fat fed diabetic NONcNZO mice exhibited higher rates of peri- and post-implantation resorption, and had aberrant expression of uterine interferon-γ and progesterone receptor (PGR) and its immunophilin co-chaperone FKBP52 at nidation (30). The aberrant PGR-targeted gene expression in PCOS-like rats pre- and post-implantation overlapped with dysregulated expression of FKBP52, which was linked to endometrial dysfunction and infertility (31).

The results in the present experiments revealed that the PM group had higher mRNA and protein levels of FKBP52 (Figs. 2 and 3) and AR (Fig. 3). This suggested that the overexpression of FKBP52 and AR in the ovaries of PCOS rats may be attributed to the stimulation of hyperandrogenism.

Morphology and identification of GCs

The H&E staining showed that cells were polygonal or cuboidal under inverted phase contrast microscopy. As FSHR is a unique marker of GCs, its positive rate in IHC and IF staining was >95%. Therefore, the above results indicated that the GCs extracted met the requirements of subsequent trials (Fig. 4).

Adenovirus vector transfection of GCs

GCs have different MOIs when they meet different viral titers. An appropriate MOI not only guarantees the transfection rate, but also conserves virus usage. In the preliminary trial, when the cell transfection rate reached ~80%, the MOI was calculated using the formula described above. This met the requirements of subsequent trials (Fig. 5).

Activated AR in the cytoplasm may interact with several signaling molecules, which in turn converge on MAPK/ERK activation (15,16). In the present study, the PM rats had higher expression levels of FKBP52, AR and p-ERK1/2 in the ovary. Therefore, it was hypothesized that FKBP52 mediates AR through the MAPK/ERK pathway. The Ad-siRNA-FKBP4-EGFP and Ad-Oe-FKBP4-EGFP adenovirus vectors were constructed to verify the association of FKBP52, AR and MAPK/ERK by transfecting GCs.

When FKBP4 was overexpressed, the mRNA and expression levels of FKBP52 and AR increased and that of p-ERK1/2 increased, whereas ERK1/2 showed no change (Fig. 6A and B). Following FKBP4 silencing, the mRNA and expression levels of FKBP52 and AR decreased, that of p-ERK1/2 increased and that of ERK1/2 decreased (Fig. 6C and D). This may be interpreted as the existence of a compensatory response and this requires verification in the future. To the best of our knowledge, this is the first time the above-mentioned results have been reported. To a certain extent, these results explain the association of FKBP52, AR and MAPK/ERK, and further verification is required to confirm this.

Acknowledgments

Not applicable.

Abbreviations

FKBP52

FK-506 binding protein 52

PCOS

polycystic ovarian syndrome

AR

androgen receptor

DHEA

dehydroepiandrosterone

ELISA

enzyme-linked immunosorbent assay

H&E

hematoxylin and eosin

IHC

immunohistochemistry

RT-qPCR

reverse transcription-quantitative polymerase chain reaction

WB

western blotting

GC

granulosa cell

SD

Sprague-Dawley

SPF

specific-pathogen-free

PBS

phosphate- buffered saline

MAPK

mitogen-activated protein kinase

ERK

extracellular signal-regulated kinase

Funding

The present study was approved the National Natural Science Foundation of China (grant no. 81674012).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

SS performed the experiments, participated in collecting data, performed the statistical analysis and drafted the manuscript. YT participated in study design and assisted in drafting the manuscript. Both authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Experimental Animal Ethics committee of Nanjing University of Chinese Medicine (Nanjing, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

  • 1.Chiofalo B, Laganà AS, Palmara V, Granese R, Corrado G, Mancini E, Vitale SG, Ban Frangež H, Vrtačnik-Bokal E, Triolo O. Fasting as possible complementary approach for poly-cystic ovary syndrome: Hope or hype. Med Hypotheses. 2017;105:1–3. doi: 10.1016/j.mehy.2017.06.013. [DOI] [PubMed] [Google Scholar]
  • 2.Asemi Z, Samimi M, Taghizadeh M, Esmaillzadeh A. Effects of Ramadan fasting on glucose homeostasis, lipid profiles, inflammation and oxidative stress in women with polycystic ovary syndrome in Kashan, Iran. Arch Iran Med. 2015;18:806–810. [PubMed] [Google Scholar]
  • 3.Franks S. Controversy in clinical endocrinology: Diagnosis of polycystic ovarian syndrome: In defense of the rotterdam criteria. J Clin Endocrinol Metab. 2006;91:786–789. doi: 10.1210/jc.2005-2501. [DOI] [PubMed] [Google Scholar]
  • 4.Qu J, Wang Y, Wu X, Gao L, Hou L, Erkkola R. Insulin resistance directly contributes to androgenic potential within ovarian theca cells. Fertil Steril. 2009;91:1990–1997. doi: 10.1016/j.fertnstert.2008.02.167. [DOI] [PubMed] [Google Scholar]
  • 5.Laganà AS, Pizzo A. Authors’ reply to: ‘Empiric’ inositol supplementation in normal-weight non-insulin resistant women with polycystic ovarian disease: From the absence of benefit to the potential adverse effects. Arch Gynecol Obstet. 2015;291:959–960. doi: 10.1007/s00404-015-3663-8. [DOI] [PubMed] [Google Scholar]
  • 6.Wang FF, Pan JX, Wu Y, Zhu YH, Hardiman PJ, Qu F. American, European, and Chinese practice guidelines or consensuses of poly-cystic ovary syndrome: A comparative analysis. J Zhejiang Univ Sci B. 2018;19:354–363. doi: 10.1631/jzus.B1700074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tai PK, Maeda Y, Nakao K, Wakim NG, Duhring JL, Faber LE. A 59-kilodalton protein associated with progestin, estrogen, androgen, and glucocorticoid receptors. Biochemistry. 1986;25:5269–5275. doi: 10.1021/bi00366a043. [DOI] [PubMed] [Google Scholar]
  • 8.Davies TH, Sánchez ER. FKBP52. Int J Biochem Cell Biol. 2005;37:42–47. doi: 10.1016/j.biocel.2004.03.013. [DOI] [PubMed] [Google Scholar]
  • 9.Cheung-Flynn J, Prapapanich V, Cox MB, Riggs DL, Suarez- Quian C, Smith DF. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol Endocrinol. 2005;19:1654–1666. doi: 10.1210/me.2005-0071. [DOI] [PubMed] [Google Scholar]
  • 10.Periyasamy S, Warrier M, Tillekeratne MP, Shou W, Sanchez ER. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms. Endocrinology. 2007;148:4716–4726. doi: 10.1210/en.2007-0145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lin JF, Xu J, Tian HY, Gao X, Chen QX, Gu Q, Xu GJ, Song JD, Zhao FK. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer. 2007;121:2596–2605. doi: 10.1002/ijc.23016. [DOI] [PubMed] [Google Scholar]
  • 12.De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, Suro RM, Garza KM, Lee S, Kim YS, et al. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci USA. 2011;108:11878–11883. doi: 10.1073/pnas.1105160108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yong W, Yang Z, Periyasamy S, Chen H, Yucel S, Li W, Lin LY, Wolf IM, Cohn MJ, Baskin LS, et al. Essential role for Co-chaperone FKBP52 but not FKBP51 in androgen receptor-mediated signaling and physiology. J Biol Chem. 2007;282:5026–5036. doi: 10.1074/jbc.M609360200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ketefian A, Jones MR, Krauss RM, Chen YD, Legro RS, Azziz R, Goodarzi MO. Association study of androgen signaling pathway genes in polycystic ovary syndrome. Fertil Steril. 2016;105:467–473. e4. doi: 10.1016/j.fertnstert.2015.09.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263–1284. doi: 10.1016/j.bbamcr.2006.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–3310. doi: 10.1038/sj.onc.1210422. [DOI] [PubMed] [Google Scholar]
  • 17.Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene. 1999;18:6322–6329. doi: 10.1038/sj.onc.1203032. [DOI] [PubMed] [Google Scholar]
  • 18.Belani M, Deo A, Shah P, Banker M, Singal P, Gupta S. Differential insulin and steroidogenic signaling in insulin resistant and non-insulin resistant human luteinized granulosa cells-A study in PCOS patients. J Steroid Biochem Mol Biol. 2018;178:283–292. doi: 10.1016/j.jsbmb.2018.01.008. [DOI] [PubMed] [Google Scholar]
  • 19.Miao ZL, Guo L, Wang YX, Cui R, Yang N, Huang MQ, Qin WB, Chen J, Li HM, Wang ZN, Wei XC. The intervention effect of Rosiglitozone in ovarian fibrosis of PCOS rats. Biomed Environ Sci. 2012;25:46–52. doi: 10.3967/0895-3988.2012.01.007. [DOI] [PubMed] [Google Scholar]
  • 20.Anderson E, Lee GY, O’Brien K. Polycystic ovarian condition in the dehydroepiandrosterone-treated rat model: Hyperandrogenism and the resumption of meiosis are major initial events associated with cystogenesis of antral follicles. Anat Rec. 1997;249:44–53. doi: 10.1002/(SICI)1097-0185(199709)249:1&#x0003c;44::AID-AR6&#x0003e;3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  • 21.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 22.Hong J, Kim ST, Tranguch S, Smith DF, Dey SK. Deficiency of co-chaperone immunophilin FKBP52 compromises sperm fertilizing capacity. Reproduction. 2007;133:395–403. doi: 10.1530/REP-06-0180. [DOI] [PubMed] [Google Scholar]
  • 23.Tranguch S, Cheung-Flynn J, Daikoku T, Prapapanich V, Cox MB, Xie H, Wang H, Das SK, Smith DF, Dey SK. Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. Proc Natl Acad Sci USA. 2005;102:14326–14331. doi: 10.1073/pnas.0505775102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Tranguch S, Wang H, Daikoku T, Xie H, Smith DF, Dey SK. FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. J Clin Invest. 2007;117:1824–1834. doi: 10.1172/JCI31622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Yang Z, Wolf IM, Chen H, Periyasamy S, Chen Z, Yong W, Shi S, Zhao W, Xu J, Srivastava A, et al. FK506-binding protein 52 is essential to uterine reproductive physiology controlled by the progesterone receptor A isoform. Mol Endocrinol. 2006;20:2682–2694. doi: 10.1210/me.2006-0024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hirota Y, Tranguch S, Daikoku T, Hasegawa A, Osuga Y, Taketani Y, Dey SK. Deficiency of immunophilin FKBP52 promotes endometriosis. Am J Pathol. 2008;173:1747–1757. doi: 10.2353/ajpath.2008.080527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Caldwell AS, Eid S, Kay CR, Jimenez M, McMahon AC, Desai R, Allan CM, Smith JT, Handelsman DJ, Walters KA. Haplosufficient genomic androgen receptor signaling is adequate to protect female mice from induction of polycystic ovary syndrome features by prenatal hyperandrogenization. Endocrinology. 2015;156:1441–1452. doi: 10.1210/en.2014-1887. [DOI] [PubMed] [Google Scholar]
  • 28.Walters KA. Role of androgens in normal and pathological ovarian function. Reproduction. 2015;149:R193–R218. doi: 10.1530/REP-14-0517. [DOI] [PubMed] [Google Scholar]
  • 29.Caldwell ASL, Edwards MC, Desai R, Jimenez M, Gilchrist RB, Handelsman DJ, Walters KA. Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome. Proc Natl Acad Sci USA. 2017;114:E3334–E3343. doi: 10.1073/pnas.1616467114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Lim JJ, Lima PDA, Salehi R, Lee DR, Tsang BK. Regulation of androgen receptor signaling by ubiquitination during folliculogenesis and its possible dysregulation in polycystic ovarian syndrome. Sci Rep. 2017;7:10272. doi: 10.1038/s41598-017-09880-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Albaghdadi AJH, Kan FWK. Immunosuppression with tacrolimus improved implantation and rescued expression of uterine progesterone receptor and its co-regulators FKBP52 and PIASy at nidation in the obese and diabetic mice: Comparative studies with metformin. Mol Cell Endocrinol. 2018;460:73–84. doi: 10.1016/j.mce.2017.07.007. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Articles from International Journal of Molecular Medicine are provided here courtesy of Spandidos Publications

RESOURCES